Tempest Therapeutics (NASDAQ:TPST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) from a sell rating to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $30.00.

Tempest Therapeutics Trading Up 12.3%

Shares of TPST stock opened at $11.53 on Friday. The business’s fifty day simple moving average is $9.86 and its 200-day simple moving average is $8.07. The company has a market cap of $51.19 million, a PE ratio of -0.79 and a beta of -2.08. Tempest Therapeutics has a 12-month low of $5.33 and a 12-month high of $20.67.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings results on Monday, August 11th. The company reported ($2.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.23) by $1.16. On average, equities analysts forecast that Tempest Therapeutics will post -1.39 earnings per share for the current year.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.